This study synthesized evidence regarding the evaluation and treatment of obesity in women across various life stages, relevant to women’s health nursing. The review examined diagnostic frameworks, including The Lancet criteria for clinical obesity and the Edmonton Obesity Staging System, alongside assessments incorporating mechanical, metabolic, mental, and social factors. These approaches complement body mass index in confirming adiposity, diagnosing illness, and staging severity. The research also considered Korean and international guidance, pharmacotherapy evidence, and literature on reproductive and menopausal physiology.
Medication selection should be based on approved indications, efficacy, safety, comorbidities, reproductive plans, access, and patient preferences. Phenotype-guided matching remains an area of ongoing investigation. Care for women of reproductive age requires addressing polycystic ovary syndrome, pregnancy intention, and specific precautions related to tirzepatide. During pregnancy and lactation, individual weight trajectories and medication safety are prioritized over pharmacologic weight loss.
Declining estradiol during the menopausal transition is linked to central fat redistribution, alongside lean mass loss associated with aging. The independent effect of follicle-stimulating hormone has not been established. Menopausal hormone therapy should be prescribed for established menopausal indications, not solely for weight loss.
Obesity care for women should integrate disease-based assessment, individualized treatment, medication counseling tailored to life stage, nonstigmatizing communication, and shared decision-making. Nurses should support assessment, education, monitoring, and coordination within their professional scope.